首页> 美国卫生研究院文献>other >Erlotinib cabozantinib or erlotinib plus cabozantinib as second- or third-line treatment of patients with EGFR wild-type advanced non-small cell lung cancer (ECOG-ACRIN 1512): a phase 2 randomised controlled trial

【2h】

Erlotinib cabozantinib or erlotinib plus cabozantinib as second- or third-line treatment of patients with EGFR wild-type advanced non-small cell lung cancer (ECOG-ACRIN 1512): a phase 2 randomised controlled trial

机译：厄洛替尼卡博替尼或厄洛替尼加卡博替尼作为EGFR野生型晚期非小细胞肺癌患者的二线或三线治疗（ECOG-ACRIN 1512）：一项2期随机对照试验

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

期刊名称 other
作者
Joel W. Neal; Suzanne E. Dahlberg; Heather A. Wakelee; Seena C. Aisner; Michaela Bowden; Ying Huang; David P. Carbone; Gregory J. Gerstner; Rachel E. Lerner; Jerome L. Rubin; Taofeek K. Owonikoko; Philip J. Stella; Preston D. Steen; Ahmed Ali Khalid; Suresh S. Ramalingam;
展开▼
作者单位

展开▼
年(卷),期 -1(17),12
年度 -1
页码 1661–1671
总页数 23
原文格式 PDF
正文语种
中图分类
关键词
Non-small cell lung cancer Erlotinib Cabozantinib Epidermal growth factor receptor;

机译：非小细胞肺癌;厄洛替尼;卡波替尼;表皮生长因子受体;
入库时间 2022-08-21 11:11:08

相似文献

外文文献
中文文献
专利

1. Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer (ECOG-ACRIN 1512): a randomised, controlled, open-label, multicentre, phase 2 trial [J] . Neal Joel W., Dahlberg Suzanne E., Wakelee Heather A., The lancet oncology . 2016,第12期

机译：厄洛替尼，卡博替尼或厄洛替尼加卡博替尼作为EGFR野生型晚期非小细胞肺癌（ECOG-ACRIN 1512）患者的二线或三线治疗：随机，对照，开放标签，多中心， 2期试验
2. Phase II Trial of Cabozantinib Plus Erlotinib in Patients With Advanced Epidermal Growth Factor Receptor ( EGFR)-Mutant Non-small Cell Lung Cancer With Progressive Disease on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy: A California Cancer Consortium Phase II Trial (NCI 9303) [J] . Karen L. Reckamp, Paul H. Frankel, Nora Ruel, Frontiers in Oncology . 2019,第2016期

机译：卡巴替尼+厄洛替尼在晚期表皮生长因子受体（ EGFR ）-突变型非小细胞肺癌中进展性疾病的表皮生长因子受体酪氨酸激酶抑制剂治疗的II期临床试验：加利福尼亚癌症协会II期试验（NCI 9303）
3. Phase II Trial of Cabozantinib Plus Erlotinib in Patients With Advanced Epidermal Growth Factor Receptor ( EGFR)-Mutant Non-small Cell Lung Cancer With Progressive Disease on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy: A California Cancer Consortium Phase II Trial (NCI 9303) [J] . Karen L. Reckamp, Paul H. Frankel, Nora Ruel, Frontiers in Oncology . 2019,第4期

机译：卡巴替尼+厄洛替尼在晚期表皮生长因子受体（ EGFR ）-突变型非小细胞肺癌中进展性疾病的表皮生长因子受体酪氨酸激酶抑制剂治疗的II期临床试验：加利福尼亚癌症协会II期试验（NCI 9303）
4. Effects of Erlotinib after Acquired Resistance to Gefitinib in Advanced Non-small-cell Lung Cancer [C] . Pan Jingjing, Shi Meiqi, Feng Jifeng Biomedical Engineering and Biotechnology (iCBEB), 2012 International Conference on . 2012

机译：吉非替尼耐药对晚期非小细胞肺癌患者的厄洛替尼治疗效果
5. Application of Quantitative Metrics for EGFR-Targeted Non-Small Cell Lung Cancer Therapy Using [11C]Erlotinib PET. [D] . Petrulli, Joseph Ryan. 2017

机译：定量指标在EGFR靶向非小细胞肺癌治疗中的应用[11C]厄洛替尼PET。
6. Phase II Trial of Cabozantinib Plus Erlotinib in Patients With Advanced Epidermal Growth Factor Receptor (EGFR)-Mutant Non-small Cell Lung Cancer With Progressive Disease on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy: A California Cancer Consortium Phase II Trial (NCI 9303) [O] . Karen L. Reckamp, Paul H. Frankel, Nora Ruel, 2007

机译：卡博替尼+厄洛替尼在晚期表皮生长因子受体（EGFR）-突变型非小细胞肺癌进展性疾病中进行表皮生长因子受体酪氨酸激酶抑制剂治疗的II期试验：加利福尼亚癌症协会II期试验（NCI 9303）
7. P1.01-113 Phase 1b Trial of Cabozantinib or Cabozantinib Plus Atezolizumab in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) [O] . F. Lim, S. Ponce, S. Patel, 2019

机译：P1.01-113 Cabozantinib或Cabozantib Plus atezolizumab的P1.01-113阶段1B试验在高级非小细胞肺癌（NSCLC）患者中

Erlotinib cabozantinib or erlotinib plus cabozantinib as second- or third-line treatment of patients with EGFR wild-type advanced non-small cell lung cancer (ECOG-ACRIN 1512): a phase 2 randomised controlled trial

著录项

相似文献

相关主题

期刊订阅